RxDoctor Payments Data

Nancy Berliner, MD

Hematology · Boston, MANPI 1609855576

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,846 of the $13,048 with a category attached, or 90.8%. 3 manufacturers reported payments, led by Sobi, Inc at 58.8% of the total. 2025 is the largest year on record at $12,177, more than ten times the $566 reported in 2020.

$13,048in general payments, 2019–2025

Across 14 payments — averaging $931.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$8K
  • Vertex$5K
  • Astrazeneca UK Limited$871
$50,214in research payments, 2019–2025

Across 6 payments — averaging $8368.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$37K
  • Swedish Orphan Biovitrum AB$10K
  • Beigene, Ltd.$2K
  • Astrazeneca UK Limited$278
  • Incyte Corporation$54

What the payments were for

  • Consulting fees$11,84691%
  • Travel & lodging$8326%
  • Food & beverage$3703%

General payments by program year

20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sobi, Inc9$7,677
Vertex2$4,500
Astrazeneca UK Limited3$871

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,048 in reported general payments places this provider in the 60th percentile of 77 hematology providers in Massachusetts.

See all hematology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$10,895
Medicare patients
80
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →